This product is an acetanilide antipyretic analgesic. It inhibits the prostaglandin synthase in the hypothalamic temperature regulation center, reduces the synthesis and release of prostaglandin PGE1, causes peripheral vasodilation and sweating, and achieves an antipyretic effect. Its antipyretic effect is similar to that of aspirin; it inhibits the synthesis and release of prostaglandin PGE1, bradykinin and histamine, increases the pain threshold and has an analgesic effect. It is a peripheral analgesic, weaker than aspirin, and is only effective for mild and moderate pain. This product has no obvious anti-inflammatory effect.

No specific pharmacological information is provided

This product is a broad-spectrum antibacterial agent with bactericidal effect at high concentrations. Many Rickettsia, Mycoplasma, Chlamydia, and Spirochete are sensitive to this product, while Enterococcus is resistant to it. Due to the widespread use of tetracyclines over the years, common clinical pathogens are seriously resistant to tetracyclines, including Gram-positive bacteria such as Staphylococcus and most Enterobacteriaceae. There is cross-resistance between this product and different varieties of tetracyclines. The mechanism of action of this product is that the drug can specifically bind to the A position of the 30S subunit of the bacterial ribosome, inhibit the growth of the peptide chain and affect the synthesis of bacterial proteins.